ATE389724T1 - Menschliche dnase i hyperaktive varianten - Google Patents

Menschliche dnase i hyperaktive varianten

Info

Publication number
ATE389724T1
ATE389724T1 AT97929686T AT97929686T ATE389724T1 AT E389724 T1 ATE389724 T1 AT E389724T1 AT 97929686 T AT97929686 T AT 97929686T AT 97929686 T AT97929686 T AT 97929686T AT E389724 T1 ATE389724 T1 AT E389724T1
Authority
AT
Austria
Prior art keywords
variants
human dnase
hyperactive
hyperactive variants
relates
Prior art date
Application number
AT97929686T
Other languages
English (en)
Inventor
Robert LAZARUS
Clark Pan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389724T1 publication Critical patent/ATE389724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97929686T 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten ATE389724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/663,831 US6391607B1 (en) 1996-06-14 1996-06-14 Human DNase I hyperactive variants

Publications (1)

Publication Number Publication Date
ATE389724T1 true ATE389724T1 (de) 2008-04-15

Family

ID=24663430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929686T ATE389724T1 (de) 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten

Country Status (12)

Country Link
US (4) US6391607B1 (de)
EP (1) EP0910647B1 (de)
JP (1) JP3468778B2 (de)
AT (1) ATE389724T1 (de)
AU (1) AU737618B2 (de)
CA (1) CA2257133C (de)
DE (1) DE69738581T2 (de)
DK (1) DK0910647T3 (de)
ES (1) ES2301180T3 (de)
NZ (1) NZ333128A (de)
PT (1) PT910647E (de)
WO (1) WO1997047751A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050016668A1 (en) * 2003-06-16 2005-01-27 Lori Powers Method and apparatus for cutting through an outer layer on a container
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269359C2 (ru) * 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
WO2006130034A1 (fr) * 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
AU2003298972A1 (en) * 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9592277B2 (en) 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
EP2416156B1 (de) * 2006-10-18 2015-12-30 Periness Ltd. Verfahren zur Bestimmung der männlichen Fertilität
US8871200B2 (en) * 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US8535925B2 (en) 2009-04-10 2013-09-17 Bio-Rad Laboratories, Inc. Modified DNase compositions and methods of use thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
MX341084B (es) 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
EP2561073B1 (de) 2010-04-23 2016-08-24 University of Massachusetts Auf das zentralnervensystem abzielende vektoren und verfahren zu ihrer verwendung
EP2468870A1 (de) 2010-12-23 2012-06-27 Philip Morris Products S.A. Verfahren zur Expression von Desoxyribonuklease in Pflanzen
ES2666303T3 (es) 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US11225648B2 (en) 2015-01-04 2022-01-18 Protalix Ltd. Modified DNase and uses thereof
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
WO2017019876A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
EP3351263A1 (de) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmazeutische zusammensetzung zur behandlung oder prävention von gewebeadhäsion
DK3668972T3 (da) 2017-08-18 2025-01-13 Neutrolis Inc Konstruerede dnase-enzymer og anvendelse i terapi
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
WO2020142740A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
WO2021071733A1 (en) 2019-10-07 2021-04-15 Texas Tech University System Mutant dnase1l3 with improved serum half-life
EP4055156A2 (de) * 2019-11-08 2022-09-14 Thermo Fisher Scientific Baltics Uab Desoxyribonuklease-varianten und verwendungen davon
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
EP4225903A1 (de) 2020-10-07 2023-08-16 Protalix Ltd. Langwirkende dnase
JP2024507220A (ja) 2021-02-19 2024-02-16 セリピオン， インコーポレイテッド パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449968B1 (de) 1988-12-23 1999-02-24 Genentech, Inc. Verfahren zur herstellung von menschlicher dnase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
CA2147469C (en) 1992-11-02 2008-01-29 Ann L. Daugherty Compaction assay for assessment of respiratory disease therapy
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
WO1996026278A1 (en) * 1995-02-24 1996-08-29 Genentech, Inc. HUMAN DNase I VARIANTS
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants

Also Published As

Publication number Publication date
US20080293121A1 (en) 2008-11-27
ES2301180T3 (es) 2008-06-16
US20020173025A1 (en) 2002-11-21
EP0910647A1 (de) 1999-04-28
AU737618B2 (en) 2001-08-23
JP3468778B2 (ja) 2003-11-17
CA2257133C (en) 2008-01-22
WO1997047751A1 (en) 1997-12-18
DE69738581D1 (de) 2008-04-30
US20050170365A1 (en) 2005-08-04
DK0910647T3 (da) 2008-07-21
PT910647E (pt) 2008-04-15
US6391607B1 (en) 2002-05-21
EP0910647B1 (de) 2008-03-19
CA2257133A1 (en) 1997-12-18
NZ333128A (en) 2000-08-25
DE69738581T2 (de) 2009-04-23
AU3368497A (en) 1998-01-07
US7407785B2 (en) 2008-08-05
JP2000512496A (ja) 2000-09-26

Similar Documents

Publication Publication Date Title
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
ATE330967T1 (de) An her2 bindende peptidverbindungen
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
ATE231852T1 (de) Bicyclische aromatische verbindungen
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DK0689586T3 (da) VPR-funktion og -aktivitet
ATE230027T1 (de) Menschliche dnase i varianten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE278011T1 (de) Human dnase ii
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
BG101847A (bg) Варианти на човешка дезоксирибонуклеаза i
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0910647

Country of ref document: EP